Clinical trial · Interventional
Dexmedetomidine and HIPEC
Dexmedetomidine and Inflammation in HIPEC Cases: A Case Series
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Inflammation is associated with an increased risk of cancer recurrence. Various methods have been used to decrease the inflammatory response induced by the cancer and surgery. In this study the investigators would like determine if a commonly used sedative drug (dexmedtomidine) has an impact on this inflammatory state when used as part of the anesthetic. The investigators will conduct a pilot study with 20 patients undergoing a Hyperthermic Intraperitoneal Chemotherapy (HIPEC) procedure as part of their cancer treatment. 10 patients will receive the standard of care for anesthesia during the cancer surgery and a placebo infusion of normal saline at a rate consistent to that of the study drug. 10 additional patients will receive the same standard of care anesthetic plan with the addition of an infusion of dexmeditomidine during the procedure. The investigators will measure the degree of inflammation before, during and after the surgical procedure by looking at the levels of inflammatory markers in blood samples. The goal is to determine if the addition of dexmodtomidine affects the inflammatory state of patients undergoing a HIPEC procedure. This information will be used to guide future studies aiming at decreasing cancer recurrence and improve patient outcomes.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Inflammation | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dexmedetomidine | Drug | — | UNRESOLVED |
| Placebos | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Normal Saline will be infused as per the protocol
- interventionNames
- Drug: Placebos
- type
- EXPERIMENTAL
- label
- Intervention group
- description
- Dexmedetomidine will be infused as per the protocol
- interventionNames
- Drug: Dexmedetomidine
Primary outcomes (1)
- measure
- Inflammation
- timeFrame
- 5 days
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Patients undergoing a Hyperthermic Intraperitoneal Chemotherapy (HIPEC) procedure as part of their cancer treatment at Vancover General Hospital * 18 years of age or older * Able to provide informed consent * Expected stay 5 days or greater in hospital * Presenting for HIPEC with Colon or Appendix Cancer Exclusion Criteria: * Contraindication to dexmedtomidine use including allergy or sensitivity to the drug * Pregnancy * Dementia * ASA greater than or equal to 4 * Significant liver disease * Current use of steroid or immunosuppressive medication * Mesothelioma tumour origin * Current use of clonidine * Current opioid use exceeding 30mg of oral morphine equivalents * Patient not eligible or patient refusal to have a thoracic epidural
References
Publications (0)
Data not yet available